biocore

Exelixis: A Platform Company for Oncology

Great piece, ohad, thanks so much.
Where do you see the stock going for the remainder of the year with the sword of GSK on its neck?

Poniard Pharmaceuticals: Platinum Rediscovered (Part II)

Hey Ohad, Been following your articles with great pleasure. I like the way you combine basic science and finance. I'm a PhD student in a structural biology lab and also plan to combine the two fields in the future.
I am also long EXEL ( as well as SGEN and SNTA) and I would love to read your thoughts on it. I think many EXEL shareholders that are currently in the red with their investment are looking for reasons to hold on. I am sure they would all appreicate your depth analysis of the company and why you are still bullish on it.


looking forward
M.T